OVID THERAPEUTICS INC. - COMMON STOCK

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

05 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

02 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

12 Nov 2024 07:00:02 By Nasdaq GlobeNewswire

Ovid Therapeutics to Host Investor Event

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin

26 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

11 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at Upcoming September Investor Conferences

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

13 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at Upcoming August Investor Conferences

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

23 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

10 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

01 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat

17 Jun 2024 05:55:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 06:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

04 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

08 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire